Diterpene ginkgolides meglumine injection (DGMI) is a therapeutic extract of L, which has been used for the treatment of cerebral ischemic stroke in China. Ginkgolides A, B and C are the main components of DGMI. This study was designed to investigate the neuroprotective effects of DGMI components against ischemic stroke in vivo and in vitro. Acute cerebral ischemic injury was induced in rats by occlusion of the middle cerebral artery (MCA) for 1.5 h followed by 24 h reperfusion. The rats were treated with nuclear translocation of nuclear factor-erythroid 2-related factor 2 (Nrf2) and phosphorylation of the survival regulatory protein cyclic AMP-responsive element binding protein (CREB). Nrf2 activation led to expression of the downstream protein heme oxygenase-1 (HO-1). In addition, PC12 cells were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) in vitro, treatment with DGMI (1, 10 and 20 g/mL) or ginkgolides A, B or C (10 Akt, nuclear translocation of Nrf2 and activation of CREB. Activation of Nrf2 and CREB could be reversed by co-treatment with a phosphoinositide-3-kinase (PI3K) inhibitor LY294002. These observations suggest that ginkgolides act as novel extrinsic regulators activating both Akt/Nrf2 and Akt/CREB signaling pathways, protecting against cerebral ischemia/reperfusion (I/R) damage in vivo and in vitro.
Introduction
Ischemic stroke is one of the leading causes of death and severe disability around the world; however, effective pharmacological treatment for this condition is lacking [1] . Diterpene ginkgolides (ginkgolides A, B and C, Figure 1 ) are the main components of the diterpene ginkgolides meglumine injection (DGMI), extracted from the traditional Chinese medicine Ginkgo biloba L, and have been used clinically for the treatment of cerebral ischemic stroke in China.
The PI3K/Akt signaling pathway has been reported to act as a key regulator in cell death and survival. In ischemic stroke, phosphorylation of Akt leads to further phosphorylation of various downstream proteins, including Nrf2 and CREB, that protect cells from ischemic damage. CREB, as a nuclear transcription factor, is activated by Akt through phosphorylation of Ser133 [2] [3] [4] [5] , facilitating CREB-binding protein (CBP) translocation to the promoter and triggering expression of protective proteins. Among them, the apoptosis regulator Bcl-2 [6] [7] [8] prevents activation of apoptosis by inhibiting the release of cytochrome c, production of reactive oxygen species (ROS) and the loss of mitochondrial membrane potential (MMP). Nrf2 regulates the transcription and expression of various antioxidant proteins through interaction with the antioxidant response element (ARE), one of the most important reported endogenous antioxidant stress pathways [9] . As a member of the Cap'n'Collar (CNC) transcription factor family, Nrf2 has a highly conserved basic leucine zipper (bZip) structure. Normally, Nrf2 binds to the Kelch-like ECH-associated protein-1 (Keap1) in the cytoplasm and is degraded through the Cullin 3-based E3-ligase ubiquitination complex-mediated pathway. Once stimulated by external stimuli or ROS, Nrf2 is released from the complex and translocates to the nucleus, where it a heterodimer and then communicates with ARE to activate the transcription of related phase II detoxifying antioxidant enzyme genes [10] [11] [12] . HO-1 is one of the phase II detoxifying enzymes and plays important roles in anti-oxidation protection in ischemia/reperfusion [13] [14] . Upregulation of HO-1 by drug treatment has shown neuroprotective effects both in vivo and in vitro [15] [16] dant response pathway protects the brain against I/R injury [17] . Therefore, regulation of Akt/Nrf2 and Akt/CREB signaling pathways might be a promising strategy for the treatment of ischemic stroke.
Ginkgo biloba L, also known as Ginkgo, has various medical effects as a traditional Chinese medicine. It was recorded in the "Compendium of Materia Medica" that Ginkgo had the effect of "dispersing toxin" [18] . The ancient Chinese phrase oxidative state in the human body. The phrase "dispersing and anti-oxidation studies of Ginkgo in stroke. The "Encyclopedia of Chinese Herbal Medicines" is an assembly of Chinese herbal medicines used in ancient China. In this book, the nature product Ginkgo was recorded for the treatment of brain stroke and myocardial infarction [19] . Currently, Ginkgo biloba L. extracts have shown various pharmacological effects, especially protective effects against I/R injury [20] [21] [22] . DGMI and EGb761 are two clinically used therapeutic extracts of Ginkgo biloba -ishia [23] and have shown various medical effects, including therapeutic action on myocardial injury and stroke [24] [25] . It has been reported that ginkgolide B, one of the main constituents of DGMI, decreases cisplatin-induced ROS generation by reducing NADPH oxidase 2 (NOX2) expression and inducing Nrf2 translocation [26] . Therefore, in this study, the protective effects of DGMI and its single components (ginkgolides A, B and C) against I/R were investigated both in vitro and in vivo. Underlying molecular mechanisms were also investigated.
Materials and methods
Reagents and chemicals DGMI was obtained from Jiangsu Kanion Pharmaceutical Co Ltd (Lianyungang, China) with national medicine permission number Z20120024 and batch number 140608, containing ginkgolide A 35%, ginkgolide B 60%, ginkgolide C 2%, ginkgolide K 2%, and 5 mg total ginkgolides per mL, analyzed by an HPLC-ELSD method that we previously developed [27] .
Shanghai Yuanye Bio-Technology Co Ltd (Shanghai, China). A 10 mmol/L stock solution of ginkgolides A, B and C was Edaravone injection was purchased from Simcere Pharmaceutical Company (Nanjing, China) with national medicine permission number H20031341 and batch number 040285. The suture used in the middle cerebral artery occlusion/reperfusion (MCAO/R) model was purchased from Cinontech Co Ltd (Beijing, China). The TUNEL apoptosis detection kit was purchased from Roche (Mannheim, Germany). Hoechst 33258, DAPI and 3- [4,5-dimethyl-2-thiazolyl ]-2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (MO, USA). Antibodies against cleaved caspase 3, Bcl-2, Bax, Akt, p-Akt and GAPDH were purchased from Cell Signaling Technology (MA, USA). Antibodies against Nrf2, CREB, Rats were anesthetized with 10% chloral hydrate (380 mg/kg), and the right common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) were isolated and ligated. To induce cerebral ischemia, a from CCA into ICA and advanced to middle cerebral artery -ate reperfusion. The body temperature of animals was mainAnimals were randomly divided into six groups: sham (n=40), vehicle (n=40), DGMI (1, 3 and 10 mg/kg, n=40 for each group) and edaravone (5 mg/kg, n=20). Edaravone was used as a free radical scavenger for a positive control. Rats were intravenously treated with vehicle, DGMI or edaravone at the onset of reperfusion and 12 h after the reperfusion.
Neurological tests were performed by an investigator blinded to the experimental design as described before [28] . Neurologi--left; 3: falling to the left; and 4: unable to walk spontaneously with depressed levels of consciousness. After I/R injury, rats with a score of 0 or 4 were not used for further study. After exclusions, there were 40 rats in the sham group, 36 rats in the vehicle group, 37 rats in the DGMI (1 mg/kg) group, 38 rats in the DGMI (3 and 10 mg/kg) groups, and 19 rats in the edaravone group used for further study. -square box (50 cm×50 cm×50 cm) for 10 min. The movement route of each rat over 10 min was tracked and recorded by a camera above the box. The recorded videos were further analyzed by animal behavior analysis software (Shanghai Xinruan Information Technology Co Ltd, SuperMaze V2.0, Shanghai, China). -ficed, and brains were quickly removed and dissected into two halves along the sagittal suture. Ischemic and normal and weights, both before and after drying, were obtained. Brain water content (%) was calculated as (wet weight -dry weight)/wet weight×100%. Cerebral edema (%) = (ischemic brain water content -normal brain water content)/normal brain water content×100%.
before being dissected into 2 mm coronal sections. Brain secunstained (white), whereas normal tissues stained red. Brains were photographed, and the infarct areas were calculated by an investigator blinded to the experimental groups using NIH ImageJ software (National Institutes of Health, Bethesda, MD, USA). Infarct volumes were obtained by multiplying brain slice thickness (2 mm) by the infarct area. Results were expressed as a percentage of total hemisphere volume.
The ischemic penumbra of the cortex in I/R injury rats or the corresponding cortex region in control rats was used for immunofluorescence assay. For TUNEL and NeuN double labeling, brain tissue slices were incubated in proteinase K solution for 30 min at room temperature. After the brain slices were washed with PBS three times, the buffer solution was added and incubated at room temperature for 20 min. Then, the reaction solution was added and incubated for 60 min. Next, 2×saline sodium citrate was added and incubated for 15 min. After washed with PBS three times, slices were placed in 0.5% Triton X-100 solution for 20 min, after which 10% goat serum was added and incubated for 30 min. Then, primary antibody for NeuN was added and incubated overnight. After the brain slices were washed with PBS three times, the secondary antibody was added and incubated at room temperature for 1 h. Then, DAPI was added and incubated for 10 min. Immunofluorescence images were acquired using a fluorescence microscope. For FJB and NeuN double labeling, brain tissue was first incubated in 0.0001% FJB dye (containing 0.1% acetic acid) for 30 min at room temperature and then rinsed three times with PBS. Sections were then incubated for 20 min in 0.5% Triton X-100 solution, followed by incubation in 10% goat serum for 30 min. The primary antibody for NeuN was then added and incubated overnight. After the brain slices were washed with PBS three times, the secondary antibody was added and incubated at room temperature for 1 h. Then, DAPI was added For Nrf2 or p-CREB double-labeled staining, the slices were placed in 0.5% Triton X-100 solution for 20 min, followed by 10% goat serum for 30 min. Then, primary antibodies for Nrf2, p-CREB and NeuN were added and incubated overnight. After the brain slices were washed with PBS three 1262 www.nature.com/aps Zhang W Acta Pharmacologica Sinica times, secondary antibodies were added and incubated at room temperature for 1 h. Then, DAPI was added and incu-PC12 cell culture and OGD/R PC12 cells were purchased from China Infrastructure of Cell Line Resources, Chinese Academy of Medical Sciences. Cells were cultured in polystyrene flasks or 96-well plates with RPMI-1640 medium containing 5% fetal bovine serum, 10% -cin under a humidified atmosphere of 95% air and 5% CO 2 . Cell culture medium was carefully replaced every 48 h. To RPMI-1640 and then incubated in glucose-free medium in a -tor (94% N 2 , 5% CO 2 and 1% O 2 ) for 4 h. After hypoxia, cells were incubated with full culture medium in the absence or presence of ginkgolide A, B or C or DGMI for 24 h. N-Acetyl-L-cysteine (NAC) was used as a positive control.
Following the above cell treatment protocol, cell viability was plates with a density of 8×10 3 cells per well. MTT reagent was on a microtiter plate shaker to dissolve the formazan product. Absorbance was measured at 570 nm using a Molecular Devices SpectraMax M5 microplate reader. Cell viability was expressed as a percentage of the untreated control.
Immunocytochemistry assay Nrf2 and p-CREB expression was detected by immunofluo-VTI high-content analysis platform. PC12 cells were cultured in black-walled optically clear-bottomed 96-well plates (Cornparaformaldehyde for 15 min following permeabilization with 0.3% Triton X-100 treatment for 10 min. Cells were blocked -cells were incubated with secondary antibody conjugated to Alexa Fluor-488 or Alexa Fluor-594 (1:500) for 1 h and Hoechst using the Cellomics ArrayScan VTI HCS Reader.
Western blot analysis
For Western blot analysis, the ischemic penumbra of cortical regions in I/R injury rats and the corresponding cortical regions in controls were used. Total protein was extracted using a Total Protein Extraction Kit following the manufacturers' protocols at 24 h, and nuclear protein was extracted using a Nuclear and Cytoplasmic Protein Extraction Kit. Protein Protein Assay Kit. Proteins were separated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE). After transferring to PVDF membranes, the membrane was blocked with 5% BSA in TBST for 2 h and incubated overnight Bax, p-Akt, Akt, Nrf2, HO-1, CREB, p-CREB, histone H3 and GAPDH. After the membrane was washed three times in TBST, antibody recognition was performed with the respective secondary antibody against HRP conjugated rabbit or mouse (1:1000 dilution) IgG for 1.5 h at room temperature. Antibodybound proteins were detected by an enhanced chemiluminescence (ECL) assay and captured through a ChemiDoc-it2 Imager (UVP, Upland, CA, USA). The optical density of the bands was analyzed using NIH ImageJ software.
Statistical analysis
All data are presented as the mean±standard deviation. Statistical analysis was carried out using the SPSS statistical package (Version 16.0; SPSS, Chicago, IL, USA) program, and the of variance (ANOVA) followed by Tukey's multiple comparison post hoc test. A P Results -sion to determine the protective effects of DGMI. As shown in Figure 2A , rats in the I/R group showed severe neurological P<0.01). The DGMI 1, 3 and 10 mg/kg groups exhibited dose-dependent decreased P<0.05, P<0.01). The positive conscores as well (P<0.01). The recorded typical movement route the DGMI treatment groups ( Figure 2C ). Water content was examined to study the protective effects of DGMI on cerebral edema. There was no cerebral edema in the sham group ( Figure 2B ). Compared to the sham group, the higher (P<0.01). The DGMI 3 and 10 mg/kg treatment groups I/R group (P<0.05 and P<0.01).
The extent of brain infarctions was assessed by TTC staining. As shown in Figure 2D and Figure 2E , the sham group showed no infarct, while the I/R group showed obvious infarct volume (P<0.01). Infarct volume was significantly decreased after treatment with DGMI at 3 or 10 mg/kg (P<0.05, P<0.01).
infarct volume (P<0.01).
I/R group compared to the sham group ( Figure 3A) , an effect that was attenuated by treatment with 3 or 10 mg/kg DGMI 1263 www.chinaphar.com Zhang W et al Acta Pharmacologica Sinica (P<0.01). As shown in Figure 3B , the ratio of Bax/Bcl-2 in group. When treated with 3 or 10 mg/kg DGMI, the ratio P<0.05, P<0.01). TUNEL and FJB staining represent the rate of apoptosis. It was found that I/R injury increased the apoptosis rate of neurons, while DGMI significantly downregulated the apoptosis rate of neurons compared to the I/R group ( Figure 3C , 3D, 3E and 3F). These results illustrate that DGMI significantly inhibits apoptosis induced by I/R.
Nrf2 is a key transcription factor that regulates expression of antioxidant genes, including HO-1, in response to oxidative stress. CREB is also an important nuclear transcription factor that triggers expression of neuro-protective proteins, including Bcl-2. As shown in Figure 4A , the 3 and 10 mg/kg DGMI -pared to the I/R group (P<0.05, P<0.01). In Figure 4B , Nrf2 protein was significantly upregulated in the DGMI 1, 3 and 10 mg/kg treatment groups compared with the I/R group (P<0.05, P<0.01). As a downstream protein of Nrf2, HO-1 was also significantly upregulated in the DGMI 3 and 10 mg/kg groups compared with the I/R group ( Figure 4C, P<0.01) . In Figure 4D , the p-CREB protein exhibited relatively low expression in the sham and I/R groups, while the DGMI 3 and 10 mg/kg groups exhibited significantly upregulated p-CREB protein expression compared with the I/R group (P<0.01).
or no Nrf2/NeuN double stained positive cells in the sham and I/R groups, while the numbers of Nrf2/NeuN double stained positive cells were significantly increased in the DGMI treatment groups ( Figure 5A and 5B, P<0.01). In addition, few p-CREB/NeuN double stained positive cells were observed in the sham and I/R groups, while the DGMI p-CREB/NeuN double stained positive cells ( Figure 5C and 5D, P<0.01). As shown in Figure 6 , OGD/R caused severe cell injury and induced cell death, while ginkgolide A, B or C treatment pro-( Figure 6A , P significantly increased cell viability ( Figure 6B , P<0.05 and P<0.01). As a scavenger of ROS, the positive control NAC also showed protective effects on PC12 cells (P<0.01).
Next, we investigated the anti-apoptotic effects of DGMI and the major components of DGMI (ginkgolides A, B and Figure 7A , cleaved caspase 3 protein was significantly upregulated in the OGD/R group compared to the control group, while P<0.05). Next, expression of the proapoptotic protein Bax and the anti-apoptotic protein Bcl-2 was investigated. As shown in Figure 7B , the ratio of Bax/Bcl-2 in the OGD/R group was significantly increased compared -ments significantly reduced the ratio of Bax/Bcl-2 (P<0.05, P<0.01). These results further show that the ginkgolide A, B or 3 expression (P<0.01, Figure 7C ). Ginkgolide A, B or C treat-P<0.01, Figure 7D ). These results indicate that ginkgolide A, B or C As shown in Figure 8A , the Akt phosphorylation level was relatively low in the normal and OGD/R groups, while DGMI treatment significantly upregulated phosphorylation of Akt (P<0.01), and the PI3K/Akt inhibitor LY294002 reversed this phenomenon (P<0.01). Next, nuclear Nrf2 levels were upregulated in the DGMI group (P<0.01), and this effect could be reversed by treatment with LY294002 (P<0.01, Figure 8B ). As shown in Figure 8C , the p-CREB level was relatively low in the normal and OGD/R groups, while DGMI treatment (P<0.01), and LY294002 reversed this induction (P<0.01). Moreover, LY294002 also reversed the downregulation of the Bax/Bcl-2 ratio induced by DGMI (P<0.01). The above results illustrate that the protective effect of DGMI may be related to regulation of the PI3K/Akt pathway.
In Figure 9 , Western blot analysis shows that treatment with -phorylation of Akt, expression of Nrf2, HO-1, and phosphorylation of CREB, which was suppressed by LY294002. Immuno-A, B or C significantly increased nuclear Nrf2 and p-CREB levels, which was reversed by the addition of LY294002 ( ure 10). These results suggest that ginkgolide A, B or C can all activate Nrf2 and p-CREB in PC12 cells exposed to OGD/R and that this effect is PI3K/Akt dependent.
Discussion
In the present study, DGMI treatment significantly reduced in neurons, activated PI3K/Akt signaling, and mediated the activation of Nrf2 and CREB. The PI3K/Akt pathway is one of the most important pathways involved in the regulation of cell survival, proliferation and differentiation that can be activated by various stimuli, including growth factors, hormones, medical drugs and xenobiotics. Nrf2 and CREB are downstream targets of the PI3K/Akt pathway, and we observed that activation of Akt signaling could trigger nuclear translocation of Nrf2 and p-CREB to promote cell survival and inhibit apoptosis [4, 12] .
Ischemia reperfusion injury immediately and acutely induces the production of intracellular ROS, causing an imbalance between oxidants and antioxidants in the brain. The damaged antioxidant defense system causes further cell dysfunction, apoptosis, autophagy and even death. Fortunately, this defense system can be maintained via the intake and selfproduction of antioxidants by the cell. Increasing the level of antioxidants is a promising strategy for the treatment of ischemic stroke. Among various regulation factors, Nrf2 and HO-1 have been suggested to be effective in promoting antioxidant production [29] . Recent studies demonstrated that HO-1 neuronal cells after cerebral ischemia reperfusion [30] [31] [32] . Upregulation of HO-1 has been shown to be protective against neuronal injury induced by oxygen-glucose deprivation [33] . In addition, Nrf2 activator has been shown to ameliorate hemorrhagic transformation in focal cerebral ischemia by protecting endothelial cells and pericytes and upregulating expression of [34] . In our study, the Nrf2 protein was -pared with the I/R group in vivo. In addition, HO-1, as one of its downstream proteins, was also significantly upregulated in the DGMI treatment groups. The results of immunofluorescence staining showed that the numbers of Nrf2/NeuN double stained positive cells were significantly increased in the DGMI treatment groups.
CREB was reported to be an effective activator of Bcl-2 [7] . As an anti-apoptotic protein, Bcl-2 inhibits intracellular ROS production and suppresses pro-apoptotic protein expression. CREB is activated by the phosphorylation of other kinases, one of which is Akt [4] . Once activated, CREB protein, together with other transcriptional coactivators, binds the CRE promoter to facilitate transcription of various genes, including Bcl-2 [7] . Upregulation of Bcl-2 by CREB activation suppressed activation of caspases, protecting the cells from apoptosis. In upregulated expression of p-CREB protein compared with the -cantly increased numbers of p-CREB/NeuN double stained positive cells in the ischemic penumbra of cortical regions.
Ginkgolides A, B and C are the major components of DGMI, and our study demonstrated that ginkgolides A, B and C reversed OGD/R-induced PC12 cell injury. In addition, ginkgolide A, B and C treatment led to an increase in the levels of Akt phosphorylation and expression of Nrf2. The accumulation of Nrf2 in the nucleus induced expression of the downstream antioxidant enzyme HO-1. CREB was also activated by ginkgolide A, B and C treatment. Interestingly, activation of Nrf2 and CREB and the neuroprotective effects of ginkgolides A, B and C were markedly attenuated when the expression of the PI3K/Nrf2 pathway was inhibited using LY294002, a PI3K inhibitor. Taken together, these in vitro our hypothesis that ginkgolides A, B and C protected against OGD/R-induced PC12 cell injury via activation of Nrf2 and CREB through PI3K/Akt signaling (Figure 11) .
In summary, this study demonstrates that DGMI ameliorates I/R injury in rats by activating the PI3K/Akt-mediated Nrf2 and CREB signaling pathway. Its major components, ginkgolides A, B and C, contributed to these protective effects, and these ginkgolides might also be developed into therapies 
